Muromachi Chemical (4885) on Oct. 15 raised its net profit forecast for the first half of the fiscal year ending May 2027 by 77.8% to ¥160 million from ¥90 million, and lifted its operating profit forecast to ¥250 million from ¥150 million, while leaving its full-year guidance unchanged.
The company, listed on the Tokyo Stock Exchange's Standard Market, said sales of imported active pharmaceutical ingredients, particularly for anti-epileptic and anti-herpes virus drugs, exceeded its initial assumptions. In its chemicals business, part of the sales of its mainstay ion exchange resins was brought forward, while sales of high-value-added products grew on an active semiconductor-related market and the company booked sales from temporary demand. The company said the upward revision includes the effects of pulled-forward sales and one-time demand.
| Item | Previous | Revised | Change |
|---|---|---|---|
| Net sales | ¥3.30 billion | ¥3.50 billion | 6.1% |
| Operating profit | ¥150 million | ¥250 million | 66.7% |
| Ordinary profit | ¥120 million | ¥240 million | 100.0% |
| Net profit | ¥90 million | ¥160 million | 77.8% |
The revised first-half forecast remains below the year-earlier result, with net sales projected down 4.9% and net profit down 34.4%. The full-year forecast stays at net sales of ¥7.10 billion and net profit of ¥350 million.
Separately, first-quarter results for June 1-Aug. 31, 2026, showed net sales up 4.1% to ¥1.86 billion, operating profit up 144.8% to ¥182 million and net profit up 147.5% to ¥142 million. Following its exit from the health food business, the company now reports two segments; pharmaceutical sales rose 21.7% and chemical sales rose 30.8%. The annual dividend forecast was kept at ¥26 per share.
Next steps: The first half ends Nov. 30, 2026. The company plans to open a chemical development center in July 2027, with renovation work on the building scheduled to start within the year.
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理,非投資建議,亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。